Drug intelligence / Profile preview

FMT + atezolizumab + bevacizumab

Development stage: Unknown
Lead developer: Sant’Orsola-Malpighi University Hospital
Modality: Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intravenous, Oral, Rectal

Overview

FMT + atezolizumab + bevacizumab is an experimental combination therapy being investigated for the treatment of unresectable hepatocellular carcinoma (HCC). This regimen is specifically designed for patients who have experienced disease progression after receiving first-line therapy with the immune checkpoint inhibitor atezolizumab and the anti-angiogenic agent bevacizumab. The therapy involves the administration of fecal microbiota transplantation (FMT) to modulate the patient's gut microbiome, which is hypothesized to play a crucial role in determining the efficacy of and resistance to immunotherapy. By altering the microbial composition, the treatment aims to 'rescue' the therapeutic response to the resumed atezolizumab and bevacizumab regimen. This approach is currently being evaluated in a Phase 2 study led by the IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Other names: fecal microbiota transplantation + atezolizumab + bevacizumabFMT plus atezolizumab and bevacizumab

Targets

VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on FMT + atezolizumab + bevacizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FMT + atezolizumab + bevacizumab.

Explore the full profile